ACE-031

ACE-031 Molecular Structure & Chemical Properties

ACE-031 peptide represents a pioneering approach to muscle regulation research through myostatin pathway inhibition. Developed by Acceleron Pharma as a soluble decoy receptor, this engineered fusion protein was designed to sequester myostatin and related negative regulators of muscle mass before they could activate cellular receptors. The compound gained orphan drug designation from the FDA in 2010 for Duchenne muscular dystrophy, reflecting substantial research interest in its therapeutic potential. Despite promising preclinical and early clinical findings demonstrating significant increases in lean muscle mass, clinical development was discontinued in 2011 due to safety concerns related to vascular side effects.

Chemical Structure

2D molecular structure (Source: PubChem)

Technical Specifications

ACE-031 is structurally distinct as a recombinant fusion protein combining the extracellular domain of human activin receptor type IIB (ActRIIB) with the Fc region of human immunoglobulin G1 (IgG1). This design confers both high-affinity ligand binding and extended circulation time through the IgG1-Fc portion.

ACE-031 Mechanism of Action

ACE-031 peptide functions as a molecular decoy receptor that intercepts and neutralizes multiple negative regulators of muscle growth before they can engage endogenous cellular receptors. The mechanism centers on competitive ligand sequestration rather than direct receptor blockade, distinguishing it from antibody-based myostatin inhibitors.

Primary Cellular Pathways

ActRIIB Ligand Sequestration – Myostatin Inhibition

Research has established that ACE-031 binds with high affinity to myostatin (GDF-8), the primary negative regulator of skeletal muscle mass[1]. This binding mechanism involves:

• Direct myostatin capture preventing interaction with endogenous ActRIIB receptors on muscle cells
• Interruption of downstream Smad2/3 signaling cascades that normally suppress muscle growth
• Blockade of myostatin’s inhibitory effects on satellite cell activation and myoblast differentiation
• Removal of growth-limiting signals allowing enhanced muscle fiber hypertrophy and hyperplasia

Studies in mdx mice (a model of muscular dystrophy) demonstrated that ACE-031 treatment significantly increased both type I and type II muscle fiber cross-sectional areas[2].

Multi-Ligand Inhibition – Activin and GDF11

Beyond myostatin, ACE-031 binds several other TGF-beta superfamily ligands that modulate muscle mass[3]:

• Activin A binding with subsequent suppression of FSH (43% reduction observed in clinical studies)
• GDF11 sequestration, another negative regulator with structural similarity to myostatin
• Potential interactions with other ActRIIB ligands in the TGF-beta superfamily
• Broader pathway inhibition compared to myostatin-specific antibodies

This multi-ligand activity explains both ACE-031’s potent muscle-building effects and the vascular side effects that emerged during clinical development.

Anabolic Signaling Enhancement

By removing inhibitory signals, ACE-031 indirectly promotes anabolic pathways in muscle tissue:

• Increased protein synthesis through removal of myostatin-mediated suppression
• Enhanced IGF-1 signaling permitting greater muscle growth potential
• Reduced proteolytic activity with decreased muscle protein breakdown
• Activation of mTOR pathways supporting muscle hypertrophy

Metabolic Effects Beyond Muscle

Research indicates ACE-031 influences multiple tissue types through its broad ligand-binding profile[4]:

• Bone metabolism modulation with increased markers of bone formation
• Fat metabolism alterations with decreased adipogenesis signaling
• Potential effects on glucose metabolism and insulin sensitivity
• Systemic metabolic changes beyond localized muscle effects

Vascular Endothelial Function – Unintended Effects

Clinical trials revealed that ACE-031’s broad ligand binding extends to factors regulating endothelial function[5]:

• Cross-inhibition of BMP9 and BMP10, critical for vascular stability
• Disruption of endothelial cell signaling leading to telangiectasias
• Minor bleeding events (epistaxis, gum bleeding) attributed to vascular fragility
• These vascular effects led to clinical development termination in 2011

ACE-031 Research Applications & Key Findings

Neuromuscular Disease Research

Duchenne Muscular Dystrophy Studies

ACE-031 was extensively studied in DMD, a fatal genetic disorder characterized by progressive muscle weakness and loss[6]. In randomized, placebo-controlled trials in ambulatory boys with DMD:

• Trends for maintenance of functional capacity measured by 6-minute walk test compared to decline in placebo groups
• Increased lean body mass demonstrated by DXA scanning
• Improved muscle volume measurements in thigh muscles via MRI
• Enhanced bone mineral density markers suggesting skeletal benefits beyond muscle

However, the Phase 2 DMD trial (study A031-03) was terminated early after the second dosing regimen due to safety concerns of epistaxis and telangiectasias, preventing completion of efficacy assessments[6].

Preclinical Neuromuscular Models

Animal studies in multiple disease models demonstrated ACE-031’s muscle-preserving effects[7]:

• mdx mouse model (DMD analog): substantial increases in muscle mass and strength with dose-dependent effects
• ALS models: prevention of muscle wasting and improved motor function
• Glucocorticoid-induced muscle loss: ACE-031 offset 11% increase in lean mass despite concurrent dexamethasone treatment
• Muscle atrophy models: consistent preservation of muscle architecture and function

Muscle Physiology Research

Muscle Mass and Strength Studies

Investigations in healthy volunteers established ACE-031’s effects on muscle tissue composition and function[1]:

• 3.3% increase in total lean body mass (P = 0.03) after single dose in postmenopausal women
• 5.1% increase in thigh muscle volume (P = 0.03) measured by MRI at day 29
• Dose-dependent responses with maximal effects at 3 mg/kg dosing
• Rapid onset with measurable changes within 4 weeks of single administration

Preclinical studies demonstrated muscle force improvements including 50% increases in maximum force generation and 25% increases in total contractile force in treated animal models[8].

Muscle Fiber Adaptations

Research examining cellular-level changes revealed[2]:

• Increased cross-sectional area of both type I and type II muscle fibers
• Enhanced satellite cell activity and myoblast proliferation
• Improved muscle fiber regenerative capacity in injury models
• Hypertrophic and hyperplastic growth mechanisms contributing to overall muscle mass gains

Metabolic and Bone Research

Bone Metabolism Effects

Clinical studies documented significant effects on bone turnover biomarkers[1]:

• 3.4% increase in lumbar spine bone mineral density in treated groups versus 1.5% decrease in controls
• Elevated serum markers of bone formation (osteocalcin, P1NP)
• Decreased markers of bone resorption (CTX, NTX)
• Potential therapeutic implications for conditions with concurrent muscle and bone loss

Fat and Metabolic Parameters

Research demonstrated ACE-031’s influence on adipose tissue and metabolism:

• Altered biomarkers of fat metabolism suggesting reduced adipogenesis
• Potential improvements in insulin sensitivity in preclinical models
• Systemic metabolic changes accompanying muscle mass increases
• Effects on body composition extending beyond muscle tissue alone

Cachexia and Muscle Wasting Research

Cancer-Related Muscle Loss

Preclinical investigations explored ACE-031 in cancer cachexia models:

• Prevention of muscle wasting in tumor-bearing animal models
• Preservation of muscle mass during chemotherapy treatment
• Potential to offset glucocorticoid-induced muscle atrophy common in cancer treatment
• Maintained muscle function despite ongoing disease processes

Androgen Deprivation and Hormonal Studies

Research examined ACE-031 in hormone-related muscle loss scenarios:

• Prevention of muscle loss during androgen deprivation therapy models
• Amelioration of estrogen deficiency effects on muscle, bone, and fat tissues
• Potential applications in aging-related muscle loss (sarcopenia)
• Hormonal therapy-induced muscle wasting prevention

ACE-031 Pharmacokinetics & Metabolism

Absorption & Distribution

ACE-031 exhibits pharmacokinetic properties characteristic of large protein therapeutics administered subcutaneously[1]. Following subcutaneous administration in human clinical studies:

• Subcutaneous bioavailability with gradual absorption from injection site into systemic circulation
• Linear pharmacokinetics with AUC and Cmax increasing proportionally with dose across 0.02-3 mg/kg range
• Wide tissue distribution reflecting the large molecular size (approximately 57 kDa) of the fusion protein
• Systemic circulation patterns typical of IgG1-Fc containing biologics

The extended plasma half-life of 10-15 days allows for infrequent dosing schedules, with clinical protocols administering ACE-031 every 2-4 weeks. This contrasts sharply with most peptide therapeutics requiring daily or more frequent administration.

Metabolism & Elimination

As a recombinant protein therapeutic, ACE-031 undergoes degradation via proteolytic pathways rather than traditional small-molecule metabolism[1]:

• Catabolism through proteolytic degradation in reticuloendothelial system and tissues
• IgG1-Fc portion recycled through FcRn-mediated salvage pathway, contributing to extended half-life
• No hepatic cytochrome P450 metabolism involved
• Breakdown into constituent amino acids ultimately incorporated into general protein pools

The 10-15 day terminal half-life represents a balance between FcRn-mediated recycling (which extends circulation time) and proteolytic degradation. This extended half-life distinguishes ACE-031 from native peptides and smaller protein fragments that typically clear within hours.

Excretion Pathways

Elimination of ACE-031 and its degradation products occurs through:

• Minimal intact protein excretion due to large molecular size preventing glomerular filtration
• Protein catabolites eliminated primarily through kidneys after proteolytic breakdown
• No detectable intact ACE-031 in urine samples from animal studies
• Degradation products too small to detect using protein-specific assays

Research in rats demonstrated that ACE-031 remained detectable in serum for at least 48 hours after single-dose administration but was undetectable by 7 days (168 hours), and no intact protein appeared in urine at any timepoint[9].

ACE-031 Research Protocols & Administration

Dosing in Published Research

Research investigations employed a range of ACE-031 doses depending on species, model, and study design:

• Human Phase 1 study: 0.02-3 mg/kg as single subcutaneous doses in healthy volunteers
• Human Phase 2 DMD study: Multiple ascending doses administered every 2-4 weeks for 12 weeks
• Mouse models: 10 mg/kg body weight typical dose in preclinical efficacy studies
• Rat pharmacokinetic studies: 10 mg/kg body weight used for detection method development

Important: These are experimental doses used in animal studies and human clinical trials and cannot be extrapolated to other species or contexts due to significant differences in metabolism, pharmacokinetics, receptor expression patterns, and species-specific responses to myostatin inhibition. Dose-response relationships vary dramatically across species.

Administration Routes in Research

Multiple delivery methods have been investigated in ACE-031 research:

• Subcutaneous injection – Primary route in human clinical trials; allows for self-administration and depot effect
• Intraperitoneal injection – Used in rodent preclinical studies for systemic delivery
• Intramuscular injection – Explored in some animal models, though less common than subcutaneous
• Intravenous injection – Used primarily for pharmacokinetic characterization studies

Subcutaneous administration was selected for clinical development due to convenient dosing interval (every 2-4 weeks), predictable absorption, and suitability for chronic therapy.

Common Model Organisms

ACE-031 has been studied across multiple research systems:

• Mice – C57BL/6J wild-type and mdx dystrophic mice; primary efficacy models for muscle-wasting conditions
• Rats – Sprague-Dawley and other strains; used for pharmacokinetic, safety, and mechanism studies
• Humans – Healthy postmenopausal women (Phase 1); ambulatory boys with Duchenne muscular dystrophy (Phase 2 – terminated early)
• Cell culture – Myoblast and endothelial cell lines for mechanistic investigations

Research Limitations & Regulatory Status

Critical Gaps in Current Evidence

Despite substantial preclinical research investment and early clinical development, ACE-031 faces fundamental translational barriers that have halted its development.

Terminated Human Clinical Development

The most significant limitation is the premature termination of all human studies:

• No completed Phase 2 trials – the DMD study was stopped after second dosing cohort
• Phase 2 extension study (A031-06) suspended with only 11 patients enrolled
• No peer-reviewed publications documenting completed therapeutic efficacy trials in humans
• Efficacy in disease states remains unproven despite promising Phase 1 data in healthy volunteers
• Development discontinued entirely in 2011 with no resumption announced

Vascular Safety Concerns

Non-muscle-related adverse events led to development termination[5,6]:

• Epistaxis (nosebleeds) observed in multiple participants across studies
• Gum bleeding and oral mucosal bleeding events
• Telangiectasias (small dilated blood vessels in skin)
• Skin erythema at various sites
• All events resolved upon discontinuation but were considered unacceptable for continued development

These vascular effects were later attributed to cross-inhibition of BMP9 and BMP10, ligands essential for endothelial cell function and vascular stability. The broad ligand-binding profile that makes ACE-031 a potent muscle builder also produces problematic off-target effects.

Lack of Mechanistic Selectivity

Fundamental mechanistic limitations remain unresolved:

• Cannot selectively inhibit myostatin without affecting activins, GDF11, and BMP9/10
• No engineering solutions identified to improve selectivity while maintaining efficacy
• Vascular side effects may be inherent to ActRIIB-based approaches
• Alternative myostatin inhibition strategies (antibodies, propeptides) may offer better selectivity

Long-Term Safety Unknown

Critical safety questions remain unanswered:

• Chronic administration effects beyond several weeks completely unknown in humans
• Potential for cumulative vascular damage with repeated dosing not assessed
• Cancer risk from sustained myostatin/activin inhibition not evaluated
• Reproductive and developmental effects inadequately studied
• Interaction potential with other medications uncharacterized

Regulatory & Competitive Sport Status

FDA Position

ACE-031 has not received FDA approval and development has been discontinued:

• Orphan drug designation granted in 2010 for Duchenne muscular dystrophy treatment
• FDA Fast Track designation obtained in 2010
• Development terminated in 2011 following Phase 2 safety data review
• Not approved for human or veterinary use in any indication
• Not legally available for medical compounding in the United States
• No active INDs or clinical development programs

The FDA’s review of safety data from the terminated trials contributed to Acceleron’s decision to discontinue development permanently.

WADA Prohibition

The World Anti-Doping Agency explicitly prohibits ACE-031 under competitive sport regulations:

• Listed in Section S4.3 – Agents Preventing Activin Receptor IIB Activation
• Specifically identified as example of “decoy activin receptors” on prohibited list
• Prohibited at all times (both in-competition and out-of-competition)
• No Therapeutic Use Exemptions (TUEs) available for any indication
• Detection methods developed and validated for anti-doping testing[9]

WADA’s 2019 list update specifically named ACE-031 as a prohibited substance, recognizing its potential for performance enhancement through muscle mass increases. Research indicates black market ACE-031 products are detectable in serum for at least 48 hours after administration[9].

Collaboration Termination

In May 2013, Acceleron Pharma and Shire PLC announced termination of their collaboration on ACE-031 and related molecules, confirming no plans to restart development. This formal discontinuation followed the 2011 clinical hold and represented the definitive end of the program.

Research Classification: ACE-031 is available only for laboratory research use. It is not intended for human consumption, medical use, or veterinary applications. All research must be conducted under appropriate ethical oversight and regulatory compliance with institutional review board approval where applicable.

References

1. Attie, K.M., Borgstein, N.G., Yang, Y., Condon, C.H., Wilson, D.M., Pearsall, A.E., Kumar, R., Willins, D.A., Seehra, J.S., & Sherman, M.L. (2013). A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle & Nerve, 47(3), 416-423. PubMed
   
2. Saitoh, M., Ishida, J., Ebner, N., Anker, S.D., Springer, J., & von Haehling, S. (2017). Myostatin inhibitors as pharmacological treatment for muscle wasting and muscular dystrophy. Journal of Cachexia, Sarcopenia and Muscle – Clinical Reports, 2(1), 1-10.
3. Lach-Trifilieff, E., Minetti, G.C., Sheppard, K., Ibebunjo, C., Feige, J.N., Hartmann, S., Brachat, S., Rivet, H., Koelbing, C., Morvan, F., Hatakeyama, S., & Glass, D.J. (2014). An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Molecular and Cellular Biology, 34(4), 606-618. PubMed
   
4. Ruckle, J., Jacobs, M., Kramer, W., Pearsall, A.E., Kumar, R., Underwood, K.W., Seehra, J., Yang, Y., Condon, C.H., & Sherman, M.L. (2009). Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. Journal of Bone and Mineral Research, 24(4), 744-752. PubMed
   
5. Suh, J., & Lee, Y.S. (2020). Myostatin inhibitors: Panacea or predicament for musculoskeletal disorders? Journal of Bone Metabolism, 27(3), 151-165. PubMed
   
6. Campbell, C., McMillan, H.J., Mah, J.K., Tarnopolsky, M., Selby, K., McClure, T., Wilson, D.M., Sherman, M.L., Escolar, D., & Attie, K.M. (2017). Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial. Muscle & Nerve, 55(4), 458-464. PubMed
   
7. Cadena, S.M., Tomkinson, K.N., Monnell, T.E., Spaits, M.S., Kumar, R., Underwood, K.W., Pearsall, R.S., & Lachey, J.L. (2010). Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type. Journal of Applied Physiology, 109(3), 635-642. PubMed
   
8. Lach-Trifilieff, E., Minetti, G.C., Sheppard, K., Ibebunjo, C., Feige, J.N., Hartmann, S., Brachat, S., Rivet, H., Koelbing, C., Morvan, F., Hatakeyama, S., & Glass, D.J. (2014). An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Molecular and Cellular Biology, 34(4), 606-618. PubMed
   
9. Reichel, C., Abzieher, F., & Geyer, H. (2025). Gel electrophoretic detection of black market ACE-031. Drug Testing and Analysis, 17(5), 456-465.
10. Acceleron Pharma. (May 2, 2013). Acceleron Pharma and Shire announce conclusion of collaboration on ACE-031 program. Company announcement.

All references open in new window. These citations are provided for educational and research purposes only. This information is not intended to diagnose, treat, cure, or prevent any disease. ACE-031 is intended for laboratory research use only.